92 related articles for article (PubMed ID: 23426948)
1. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.
DeKelver RC; Yan M; Ahn EY; Shia WJ; Speck NA; Zhang DE
Blood; 2013 May; 121(18):3714-7. PubMed ID: 23426948
[TBL] [Abstract][Full Text] [Related]
2. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.
Yan M; Burel SA; Peterson LF; Kanbe E; Iwasaki H; Boyapati A; Hines R; Akashi K; Zhang DE
Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17186-91. PubMed ID: 15569932
[TBL] [Abstract][Full Text] [Related]
3. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.
DeKelver RC; Lewin B; Weng S; Yan M; Biggs J; Zhang DE
Leuk Lymphoma; 2014 Apr; 55(4):884-91. PubMed ID: 23772668
[TBL] [Abstract][Full Text] [Related]
4. Pontin is a critical regulator for AML1-ETO-induced leukemia.
Breig O; Bras S; Martinez Soria N; Osman D; Heidenreich O; Haenlin M; Waltzer L
Leukemia; 2014 Jun; 28(6):1271-9. PubMed ID: 24342949
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J
J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087
[TBL] [Abstract][Full Text] [Related]
6. PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential.
Shia WJ; Okumura AJ; Yan M; Sarkeshik A; Lo MC; Matsuura S; Komeno Y; Zhao X; Nimer SD; Yates JR; Zhang DE
Blood; 2012 May; 119(21):4953-62. PubMed ID: 22498736
[TBL] [Abstract][Full Text] [Related]
7. Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
Dou L; Yan F; Pang J; Zheng D; Li D; Gao L; Wang L; Xu Y; Shi J; Wang Q; Zhou L; Shen N; Singh P; Wang L; Li Y; Gao Y; Liu T; Chen C; Al-Kali A; Litzow MR; Chi YI; Bode AM; Liu C; Huang H; Liu D; Marcucci G; Liu S; Yu L
Nat Commun; 2019 Nov; 10(1):5051. PubMed ID: 31699991
[TBL] [Abstract][Full Text] [Related]
8. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
Gelmetti V; Zhang J; Fanelli M; Minucci S; Pelicci PG; Lazar MA
Mol Cell Biol; 1998 Dec; 18(12):7185-91. PubMed ID: 9819405
[TBL] [Abstract][Full Text] [Related]
9. Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Thiel VN; Giaimo BD; Schwarz P; Soller K; Vas V; Bartkuhn M; Blätte TJ; Döhner K; Bullinger L; Borggrefe T; Geiger H; Oswald F
Leukemia; 2017 Nov; 31(11):2491-2502. PubMed ID: 28360416
[TBL] [Abstract][Full Text] [Related]
10. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
Schnoeder TM; Schwarzer A; Jayavelu AK; Hsu CJ; Kirkpatrick J; Döhner K; Perner F; Eifert T; Huber N; Arreba-Tutusaus P; Dolnik A; Assi SA; Nafria M; Jiang L; Dai YT; Chen Z; Chen SJ; Kellaway SG; Ptasinska A; Ng ES; Stanley EG; Elefanty AG; Buschbeck M; Bierhoff H; Brodt S; Matziolis G; Fischer KD; Hochhaus A; Chen CW; Heidenreich O; Mann M; Lane SW; Bullinger L; Ori A; von Eyss B; Bonifer C; Heidel FH
Blood; 2022 Feb; 139(7):1080-1097. PubMed ID: 34695195
[TBL] [Abstract][Full Text] [Related]
11. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation.
Wang L; Gural A; Sun XJ; Zhao X; Perna F; Huang G; Hatlen MA; Vu L; Liu F; Xu H; Asai T; Xu H; Deblasio T; Menendez S; Voza F; Jiang Y; Cole PA; Zhang J; Melnick A; Roeder RG; Nimer SD
Science; 2011 Aug; 333(6043):765-9. PubMed ID: 21764752
[TBL] [Abstract][Full Text] [Related]
12. CBFbeta is critical for AML1-ETO and TEL-AML1 activity.
Roudaia L; Cheney MD; Manuylova E; Chen W; Morrow M; Park S; Lee CT; Kaur P; Williams O; Bushweller JH; Speck NA
Blood; 2009 Mar; 113(13):3070-9. PubMed ID: 19179469
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.
Liu Y; Chen W; Gaudet J; Cheney MD; Roudaia L; Cierpicki T; Klet RC; Hartman K; Laue TM; Speck NA; Bushweller JH
Cancer Cell; 2007 Jun; 11(6):483-97. PubMed ID: 17560331
[TBL] [Abstract][Full Text] [Related]
14. [Co-existence of AML1-ETO and BCR-ABL1 fusion genes in acute myeloid leukemia: a case report].
Yao YQ; Jia X; Liu H; Lu QS; Xiong WJ; Zhang Y; Liu QF; Shi PC
Zhonghua Nei Ke Za Zhi; 2024 Feb; 63(2):203-206. PubMed ID: 38326048
[TBL] [Abstract][Full Text] [Related]
15. [Establishment of leukemia cell model with inducible AML1-ETO expression and its effect on fatty acid metabolism in leukemia cells].
Xie WQ; Yang X; Gu RX; Tian Z; Xing HY; Tang KJ; Rao Q; Qiu SW; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):366-372. PubMed ID: 37550185
[No Abstract] [Full Text] [Related]
16. ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias.
Golovine K; Abalakov G; Lian Z; Chatla S; Karami A; Chitrala KN; Madzo J; Nieborowska-Skorska M; Huang J; Skorski T
Blood Cancer J; 2023 Mar; 13(1):42. PubMed ID: 36959186
[TBL] [Abstract][Full Text] [Related]
17. Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation.
Yan M; Liu M; Davis AG; Stoner SA; Zhang DE
Leukemia; 2024 Jan; 38(1):31-44. PubMed ID: 37838757
[TBL] [Abstract][Full Text] [Related]
18. RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia.
van der Kouwe E; Staber PB
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654457
[TBL] [Abstract][Full Text] [Related]
19. RUNX1: A microRNA hub in normal and malignant hematopoiesis.
Rossetti S; Sacchi N
Int J Mol Sci; 2013 Jan; 14(1):1566-88. PubMed ID: 23344057
[TBL] [Abstract][Full Text] [Related]
20. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.
Martinez-Soria N; McKenzie L; Draper J; Ptasinska A; Issa H; Potluri S; Blair HJ; Pickin A; Isa A; Chin PS; Tirtakusuma R; Coleman D; Nakjang S; Assi S; Forster V; Reza M; Law E; Berry P; Mueller D; Osborne C; Elder A; Bomken SN; Pal D; Allan JM; Veal GJ; Cockerill PN; Wichmann C; Vormoor J; Lacaud G; Bonifer C; Heidenreich O
Cancer Cell; 2019 Apr; 35(4):705. PubMed ID: 30991028
[No Abstract] [Full Text] [Related]
[Next] [New Search]
